Difference between revisions of "Plenge 2012 Endocrine Abstracts"
| Line 1: | Line 1: | ||
{{Publication | {{Publication | ||
|title=Plenge U, Guadeloupe-Grau A, Andersen P, Carsten L, Dela F, Pott F, Jørn H, Belhage B, Boushel | |title=Plenge U, Guadeloupe-Grau A, Andersen P, Carsten L, Dela F, Pott F, Jørn H, Belhage B, Boushel RC (2012) Recombinant erythropoietin treatment enhances mitochondrial function in human skeletal muscle. Endocrine Abstracts 29 P302 . | ||
|info=[http://www.endocrine-abstracts.org/ea/0029/ea0029P302.htm European Society of Endocrinology] | |info=[http://www.endocrine-abstracts.org/ea/0029/ea0029P302.htm European Society of Endocrinology] | ||
|authors=Plenge U, Guadeloupe-Grau A, Andersen P, Carsten L, Dela F, Pott F, Joern H, Belhage B, Boushel | |authors=Plenge U, Guadeloupe-Grau A, Andersen P, Carsten L, Dela F, Pott F, Joern H, Belhage B, Boushel RC | ||
|year=2012 | |year=2012 | ||
|journal=Endocrine Abstracts | |journal=Endocrine Abstracts | ||
|abstract=Erythropoietin (Epo) treatment has been shown to induce mitochondrial biogenesis in cardiac muscle along with enhanced mitochondrial capacity in mice. We hypothesized that recombinant human Epo (rhEpo) treatment enhances skeletal muscle mitochondrial oxidative phosphorylation (OXPHOS) capacity in humans. In six healthy volunteers rhEpo was administered by s.c. injection over eight weeks with oral iron (100 mg) supplementation taken daily. Mitochondrial OXPHOS was quantified by high-resolution respirometry in saponin-permeabilized muscle fibers obtained from biopsies of the vastus lateralis before and after rhEpo treatment. OXPHOS was determined with the mitochondrial complex I substrates malate, glutamate, pyruvate and complex II substrate succinate in the presence of saturating ADP concentrations, while maximal electron transport capacity (ETS) was assessed by addition of an uncoupler. rhEpo treatment increased OXPHOS (from 92±5 to 113±7 pmol/s per mg) and ETS (107±4 to 143±14 pmol/s per mg, P<0.05), demonstrating that Epo treatment induces an upregulation of OXPHOS and ETS in human skeletal muscle. | |abstract=Erythropoietin (Epo) treatment has been shown to induce mitochondrial biogenesis in cardiac muscle along with enhanced mitochondrial capacity in mice. We hypothesized that recombinant human Epo (rhEpo) treatment enhances skeletal muscle mitochondrial oxidative phosphorylation (OXPHOS) capacity in humans. In six healthy volunteers rhEpo was administered by s.c. injection over eight weeks with oral iron (100 mg) supplementation taken daily. Mitochondrial OXPHOS was quantified by high-resolution respirometry in saponin-permeabilized muscle fibers obtained from biopsies of the vastus lateralis before and after rhEpo treatment. OXPHOS was determined with the mitochondrial complex I substrates malate, glutamate, pyruvate and complex II substrate succinate in the presence of saturating ADP concentrations, while maximal electron transport capacity (ETS) was assessed by addition of an uncoupler. rhEpo treatment increased OXPHOS (from 92±5 to 113±7 pmol/s per mg) and ETS (107±4 to 143±14 pmol/s per mg, P<0.05), demonstrating that Epo treatment induces an upregulation of OXPHOS and ETS in human skeletal muscle. | ||
|keywords=Erythropoietin (Epo) | |keywords=Erythropoietin (Epo) | ||
|mipnetlab=DK Copenhagen Boushel | |mipnetlab=DK Copenhagen Boushel RC, DK Copenhagen Dela F, | ||
}} | }} | ||
{{Labeling | {{Labeling | ||
Revision as of 15:26, 16 May 2012
| Plenge U, Guadeloupe-Grau A, Andersen P, Carsten L, Dela F, Pott F, Jørn H, Belhage B, Boushel RC (2012) Recombinant erythropoietin treatment enhances mitochondrial function in human skeletal muscle. Endocrine Abstracts 29 P302 . |
» European Society of Endocrinology
Plenge U, Guadeloupe-Grau A, Andersen P, Carsten L, Dela F, Pott F, Joern H, Belhage B, Boushel RC (2012) Endocrine Abstracts
Abstract: Erythropoietin (Epo) treatment has been shown to induce mitochondrial biogenesis in cardiac muscle along with enhanced mitochondrial capacity in mice. We hypothesized that recombinant human Epo (rhEpo) treatment enhances skeletal muscle mitochondrial oxidative phosphorylation (OXPHOS) capacity in humans. In six healthy volunteers rhEpo was administered by s.c. injection over eight weeks with oral iron (100 mg) supplementation taken daily. Mitochondrial OXPHOS was quantified by high-resolution respirometry in saponin-permeabilized muscle fibers obtained from biopsies of the vastus lateralis before and after rhEpo treatment. OXPHOS was determined with the mitochondrial complex I substrates malate, glutamate, pyruvate and complex II substrate succinate in the presence of saturating ADP concentrations, while maximal electron transport capacity (ETS) was assessed by addition of an uncoupler. rhEpo treatment increased OXPHOS (from 92±5 to 113±7 pmol/s per mg) and ETS (107±4 to 143±14 pmol/s per mg, P<0.05), demonstrating that Epo treatment induces an upregulation of OXPHOS and ETS in human skeletal muscle. • Keywords: Erythropoietin (Epo)
• O2k-Network Lab: DK Copenhagen Boushel RC, DK Copenhagen Dela F
Labels:
Organism: Human
Tissue;cell: Skeletal muscle
Preparation: Permeabilized tissue
Enzyme: Complex I, Complex II; Succinate Dehydrogenase"Complex II; Succinate Dehydrogenase" is not in the list (Adenine nucleotide translocase, Complex I, Complex II;succinate dehydrogenase, Complex III, Complex IV;cytochrome c oxidase, Complex V;ATP synthase, Inner mt-membrane transporter, Marker enzyme, Supercomplex, TCA cycle and matrix dehydrogenases, ...) of allowed values for the "Enzyme" property.
Regulation: Respiration; OXPHOS; ETS Capacity"Respiration; OXPHOS; ETS Capacity" is not in the list (Aerobic glycolysis, ADP, ATP, ATP production, AMP, Calcium, Coupling efficiency;uncoupling, Cyt c, Flux control, Inhibitor, ...) of allowed values for the "Respiration and regulation" property.
HRR: Oxygraph-2k
